GW28-e0119 Ticagrelor in Patients With Non-Clopidogrel Resistance After Percutaneous Coronary Intervention

International multicenter clinical research (PLATO) confirmed that ticagrelor as a new type drug with stronger antithrombotic effect, significantly reduced the cardiovascular mortality and improved the prognosis of patients. At the same time, ticagrelor did not increase the risk of bleeding. However